AVDL
Avadel PharmaceuticalsAVDL
AVDL
About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Employees: 188
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 26
29% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 45
9% more funds holding
Funds holding: 157 [Q4 2024] → 171 (+14) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]
1.97% less ownership
Funds ownership: 82.28% [Q4 2024] → 80.31% (-1.97%) [Q1 2025]
27% less capital invested
Capital invested by funds: $833M [Q4 2024] → $611M (-$222M) [Q1 2025]
44% less call options, than puts
Call options by funds: $2.25M | Put options by funds: $3.99M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$19
99%
upside
Avg. target
$19
99%
upside
High target
$19
99%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia | 99%upside $19 | Buy Reiterated | 8 May 2025 |
Financial journalist opinion
Based on 5 articles about AVDL published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neutral
GlobeNewsWire
1 week ago
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may be clinically superior to the same drug(s) already approved for the same indication, because LUMRYZ may provide a major contribution to patient care due to its once-nightly dosing for patients with IH, a chronic sleep disorder that requires potentially lifelong treatment.
Neutral
GlobeNewsWire
2 weeks ago
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data reflecting the therapeutic results of LUMRYZ treatment in people with narcolepsy across clinical as well as real-world settings will be presented – DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 posters at SLEEP 2025, the 39th Annual Meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. “Post-hoc analysis of the pivotal Phase 3 REST-ON clinical trial, restricted to those study participants with the most severe sleepiness at baseline as measured both objectively and subjectively, showed LUMRYZ participants with a median Epworth Sleepiness Scale (ESS) score at Week 13 that was improved to the range at or below that considered normal.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
2 weeks ago
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 10:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy
Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Seeking Alpha
1 month ago
Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'
Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter the idiopathic hypersomnia market after a favorable court ruling. Analysts remain bullish, reiterating Buy ratings and projecting significant revenue and profit growth through FY2026 as LUMRYZ adoption accelerates.
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain.
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m.
Positive
Zacks Investment Research
1 month ago
Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy?
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Charts implemented using Lightweight Charts™